Our untargeted metabolomics strategy follows a top-down approach by making use of a combination of two complementary platforms, LC-Orbitrap-MS (QExactive HFX) and GC-TOF-MS (Markes BenchTOF). Based on the outcome further targeted assays are developed and applied to the same set of samples in order to quantify specific biomarkers of interest. Our untargeted platform can be applied to various projects and matrices, such as the investigation of drug interactions, resolving drug metabolism and identification of biomarkers.
Metabolomic Fingerprinting in Various Body Fluids of a Diet-Controlled Clinical Smoking Cessation Study Using a Validated GC-TOF-MS Metabolomics Platform
Goettel M, Niessner R, Mueller D, Scherer M, Scherer G, Pluym N
Journal of Proteome Research, Volume 16(10), doi: 10.1021/acs.jproteome.7b00128.
Untargeted metabolomic profiling in saliva of smokers and nonsmokers by a validated GC-TOF-MS method
Mueller DC, Piller M, Niessner R, Scherer M, Scherer G
Journal of Proteome Research, Volume 13, doi: 10.1021/pr401099r
Urine, Plasma, Saliva
Human metabolism and urinary excretion kinetics of the UV filter Uvinul A plus® after a single oral or dermal dosage
Stoeckelhuber M, Scherer M, Peschel O, Leibold E, Bracher F, Scherer G, Pluym N
International Journal of Hygiene and Environmental Health, 227:113509, doi: 10.1016/j.ijheh.2020.113509
Development of a human biomonitoring method for assessing the exposure to ethoxyquin in the general population
Stoeckelhuber M, Scherer M, Bracher F, Peschel O, Leibold E, Scherer G, Pluym N
Archives of Toxicology, volume 94, doi: 10.1007/s00204-020-02871-7
Pioneers in biomarker research
Almost all of the biomarker methods developed at ABF were published in peer-reviewed journals, a fact that supports the validity, transparency and scientific evidence of the bioanalysis especially of importance for regulatory submissions